Skip to main content
. 2018 Feb 14;51(1):43–52. doi: 10.4143/crt.2017.562

Table 2.

Tumor responses for patients with measurable disease

IX (n=99) X (n=84) p-value
CR 4 (4.0) 1 (1.2)
PR 40 (40.4) 27 (32.1)
SD 30 (30.3) 26 (31.0)
PD 16 (16.2) 22 (26.2)
Not known 9 (9.1) 8 (9.5)
ORR 44 (44.4) 28 (33.3) 0.30

Values are presented as number (%). IX, irinotecan and capecitabine combination; X, capecitabine alone; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate (CR+PR).